The Cardiovascular Research Foundation (CRF) announced that TVT 2021 will feature 12 studies as Late-Breaking Clinical Science. An annual meeting from CRF, TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.
The program for TVT 2021: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.
The Heart Valve Collaboratory (HVC) announced today that the U.S. Food and Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) will participate in this “collaborative community”. A medical “collaboratory” is a forum in which multidisciplinary private and public sector members work together on medical device challenges to achieve aligned outcomes, solve shared problems, and leverage collective opportunities, in the interest of improving patient care.
In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.
The Cardiovascular Research Foundation (CRF) is pleased to announce that registration for the annual scientific symposium, TCT Connect, taking place online October 14-18, is free for all attendees and is now open.
PCR and CRF are pleased to announce the creation of virtual Partners in Learning sessions that will be broadcast during the PCR e-Course (June 25-27, 2020) and CRF’s TVT Connect meeting (June 18-28, 2020). The sessions, which will cover coronary artery disease in TAVI patients and TAVI in low risk patients, are part of a collaborative educational series from the two groups.
The Cardiovascular Research Foundation (CRF) has announced that TVT Connect, the Structural Heart Summit, will take place online June 18-28, 2020. TVT Connect features expertly developed series, late-breaking clinical science, challenging cases, industry-sponsored sessions, and connection to a community of thought leaders from across the globe.
While transcatheter aortic valve replacement (TAVR) continues to expand its pool of eligible patients, open heart surgery—resulting in excellent patient survival and fewer strokes when compared to TAVR—is the best option for young and middle-aged adults with aortic valve disease—at least for now.
PCR and TCT are proud to announce the creation of a new educational program: “Partners in Learning.” The first of its kind will focus on TAVI practitioners, taking place on 21-22 March 2020 in Sao Paulo, Brazil. It is the first ever stand-alone collaboration between TCT, PCR, and a regional core team of leading practitioners.
When Mick Jagger received an artificial heart valve via catheter, he made the transcatheter replacement valve famous. Iconic “Dr. Y” made it possible. Ajit Yoganathan’s lab has tested every valve on the market for quality, and his analyses shaped the industry and its designs, including of the valve in Jagger’s chest.
Robbin G. Cohen, MD, Associate Professor of Surgery at Keck School of Medicine of the University of Southern California (USC), and Director of the Huntington Memorial Hospital Cardiothoracic and Lung Cancer Surgery Program. He has written extensively and lectured worldwide…
Since August, when the FDA approved a minimally invasive heart valve procedure for an expanded group of patients with aortic stenosis, many more patients are opting for the procedure known as transcatheter aortic valve replacement (TAVR). With this latest approval, the procedure can now be performed on a wide spectrum of patients, from patients too sick to undergo open-heart surgery to those who would be considered low risk for open-heart surgery.